Advertisement
Canada markets closed
  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CAD/USD

    0.7263
    -0.0001 (-0.01%)
     
  • CRUDE OIL

    82.62
    -0.11 (-0.13%)
     
  • Bitcoin CAD

    87,443.95
    +2,723.10 (+3.21%)
     
  • CMC Crypto 200

    1,313.61
    +428.07 (+48.31%)
     
  • GOLD FUTURES

    2,394.60
    -3.40 (-0.14%)
     
  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     
  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     
  • NASDAQ futures

    17,529.25
    -18.00 (-0.10%)
     
  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • CAD/EUR

    0.6823
    +0.0021 (+0.31%)
     

BioNTech Is No Longer a Buy, Says Analyst

BioNTech Is No Longer a Buy, Says Analyst

Despite some good news recently about the coronavirus vaccine it co-developed, BioNTech (NASDAQ: BNTX) has been hit with a recommendation downgrade. In a research note published on Tuesday, Bryan Garnier analyst Olga Smolentseva changed her view on the stock to neutral from the previous buy recommendation. At the same time, though, she significantly raised her price target on the stock, from $135 per share to $206.